Detalles de la búsqueda
1.
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
Antimicrob Agents Chemother
; 65(5)2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33649107
2.
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
Antimicrob Agents Chemother
; 66(5): e0203821, 2022 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35389236
3.
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
J Antimicrob Chemother
; 76(8): 2153-2157, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33880558
4.
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Antimicrob Agents Chemother
; 63(5)2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30803969
5.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother
; 74(12): 3555-3564, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31430369
6.
Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.
J Med Virol
; 91(12): 2188-2194, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31389026
7.
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Lancet
; 390(10107): 2063-2072, 2017 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867497
8.
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet
; 390(10107): 2073-2082, 2017 Nov 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28867499
9.
Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs.
Health Promot Pract
; 19(6): 815-822, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227752
10.
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
J Infect Dis
; 215(6): 920-927, 2017 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453836
11.
Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.
Clin Infect Dis
; 62(7): 929-934, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26689956
12.
Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.
Antimicrob Agents Chemother
; 60(2): 757-65, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26574015
13.
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
Antimicrob Agents Chemother
; 60(12): 7086-7097, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27645238
14.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
HIV Clin Trials
; 17(1): 29-37, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26899540
15.
Inherited variation at MC1R and ASIP and association with melanoma-specific survival.
Int J Cancer
; 136(11): 2659-67, 2015 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25382380
16.
A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.
Antimicrob Agents Chemother
; 59(2): 838-48, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25403670
17.
Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
Antimicrob Agents Chemother
; 59(6): 3441-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25824231
18.
Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.
J Antimicrob Chemother
; 70(9): 2632-8, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26108607
19.
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
HIV Clin Trials
; 16(1): 30-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25777187
20.
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Antimicrob Agents Chemother
; 58(10): 6145-50, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092710